The Cooper Companies, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Cooper Companies Q2 Earnings Call Highlights

AI-generated analysis

πŸ“ˆ Cooper Companies reported record Q2 revenue of $1.08 billion (+8% YoY) and non-GAAP EPS of $1.21 (+26%), marking the 10th consecutive quarter of beating consensus.

πŸ‘οΈ CooperVision segment grew 8% to $724 million, led by premium lens strength in the Americas and double-digit growth for the MyDay brand.

πŸ“‰ Asia-Pacific revenue declined 6% due to consumer weakness in Japan and China, alongside a strategic shift away from legacy hydrogel products.

πŸ”¬ CooperSurgical fertility revenue increased 10% organically to $144 million, driven by U.S. strength and restocking activity in the Middle East.

βš–οΈ The company settled over 95% of claims related to a December 2023 embryo culture media recall, recording a net charge of $271.6 million.

🀝 Management confirmed robust interest from multiple parties in CooperSurgical and stated that litigation resolution removes barriers to advancing strategic discussions.

πŸ’° Free cash flow guidance for fiscal 2026 was raised to roughly $650 million, excluding litigation payouts, with a long-term target of $2.2 billion through 2028.

πŸ“Š Fiscal 2026 revenue guidance was updated to $4.28-$4.32 billion, reflecting 5-6% reported growth and 3.5-4.5% organic growth.

πŸ”„ Gross margin guidance for Q3 is lowered to around 66% due to unfavorable FX, tariffs, freight costs, and inventory reduction from a new AI system.

πŸ“‰ Cooper plans to be more aggressive on share repurchases in the future after using cash to reduce net debt to $2.3 billion this quarter.

Bullish Signals
  • Record revenue of $1.08 billion and non-GAAP EPS of $1.21 represent a 26% increase year-over-year.
  • The company has achieved 10 consecutive quarters of exceeding consensus earnings expectations.
  • CooperVision premium lenses in the Americas grew 7%, supported by strength in high-margin products.
  • CooperSurgical fertility revenue increased 10% organically, with strong performance in capital equipment and genomics.
  • The resolution of the embryo culture media litigation allows management to proceed with strategic reviews without legal hindrances.
  • Robust interest has been received from multiple parties regarding CooperSurgical, indicating high valuation potential.
  • Free cash flow guidance was raised to $650 million for fiscal 2026, excluding one-time litigation costs.
  • The company maintains a strong balance sheet with net debt reduced to $2.3 billion and a history of buybacks.
Risk Factors
  • Asia-Pacific revenue declined 6% due to consumer weakness in key markets like Japan and China.
  • A net charge of $271.6 million was recorded for the embryo culture media recall settlements, impacting GAAP earnings.
  • Gross margins are expected to decline year-over-year, with Q3 projected at around 66% due to tariffs and FX headwinds.
  • CooperVision faces challenges in Asia-Pacific where it is less strong in e-commerce channels compared to practitioner channels.
  • PARAGARD revenue was flat, which management noted was ahead of expectations but still represents stagnation.
Full Analysis
Cooper Companies (NASDAQ:COO) reported record revenue of $1.08 billion and non-GAAP earnings per share of $1.21 for the fiscal second quarter of 2026, representing an 8% year-over-year increase in revenue and a 26% rise in earnings. The company achieved its 10th consecutive quarter of beating consensus estimates, with organic consolidated revenue growth of 5%. CEO Albert White attributed results to steady execution, innovation, and market share gains, while CFO Brian Andrews noted that operating income rose 19% to an operating margin of 27.5%. The company's two main segments showed mixed but generally positive performance. CooperVision revenue increased 8% to $724 million, driven by strong growth in premium lenses in the Americas and demand for MyDay and MiSight products in Europe. However, Asia-Pacific revenue declined 6% due to portfolio repositioning and consumer weakness in Japan and China. CooperSurgical revenue rose 8% to $358 million, with fertility sales up 10% and surgical products growing 4%, though PARAGARD revenue remained flat. A significant development involves the resolution of litigation related to a December 2023 embryo culture media recall. The company reached settlements covering over 95% of claimants, recording a net charge of $271.6 million which was excluded from non-GAAP earnings. This resolution allows management to advance strategic discussions regarding CooperSurgical, with the CEO noting robust interest from multiple parties and the potential for an update before the next earnings call if progress is made. Cooper updated its fiscal 2026 guidance, raising the revenue outlook to $4.28-$4.32 billion and non-GAAP EPS guidance to $4.58-$4.66. Free cash flow guidance was raised to approximately $650 million for the year, excluding litigation payouts, with a long-term view of generating $2.2 billion in free cash flow from 2026 through 2028. Management expects gross margins to decline slightly in the third quarter due to unfavorable foreign exchange and higher costs including tariffs, but plans to be more aggressive on share repurchases following the current quarter's conservative stance.